Skip to content
AnalystLens

BeOne Medicines Ltd. 8-K Report, Financial Results (Nov 12, 2024)

Reports
Earnings & Results·Other Events·Exhibits & Filings
Filing Date
Filed November 12, 2024
Period End
November 12, 2024
Securities
ONCBEIGF
In the record · 2016–202610-K1310-Q328-K284

ONC filed 13 annual reports (10-K), 32 quarterly reports (10-Q) and 284 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’18Jan ’18
  2. Material agreement8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Jun ’22Jun ’22
  4. Leadership change8-K · Jun ’26Jun ’26

01—Abstract

Summary

Summary of the 8-K filed November 12, 2024. Cited figures are marked; the original filing is the authoritative source.

BeiGene, Ltd. (NASDAQ: BGNE; the filing predates its rename to BeOne Medicines) reported third-quarter 2024 total revenue of $1,001.6 milliona, up 28% from $781.3 million a year earlier.

The growth came from product revenue, which rose 67% to $993.4 millionb, led by BRUKINSA. U.S. BRUKINSA sales were $504 million (up 87%), and European BRUKINSA sales were $97 million (up 217%). Collaboration revenue fell 96% to $8.2 million because the prior-year period included about $183 million of recognized Novartis deferred revenue.

The prior-year comparison is therefore distorted, and the underlying product business is the better gauge of momentum. Profitability improved sharply on an adjusted basis. Adjusted operating income was $65.6 millionc, compared with an adjusted operating loss of $16.3 million a year earlier, and management described it as the second consecutive quarter of positive non-GAAP operating income.

GAAP loss from operations narrowed 10% to $120.3 milliond. GAAP net loss was $121.4 million, or $(1.15) per ADS, compared with net income of $215.4 million in the prior year, which included a $363 million BMS arbitration gain and the Novartis revenue recognition. Operating cash flow turned positive at $188.4 million, versus negative $78.2 million a year earlier.

Cash, cash equivalents and restricted cash were $2.71 billion at September 30, 2024, down from $3.19 billion at year-end 2023, while debt rose to $1.05 billion. Investors should watch the cash balance trend and the company's ability to sustain GAAP profitability as launch spending continues.

02—Key points

Key Highlights

  1. Total revenue rose 28% year over year to $1,001.6 million, and product revenue grew 67% to $993.4 million, driven mainly by BRUKINSA.
  2. BRUKINSA U.S. sales reached $504 million (up 87%), and European sales reached $97 million (up 217%). Management said more than 60% of quarter-over-quarter U.S. demand growth came from CLL.
  3. Adjusted operating income was $65.6 million, versus an adjusted loss of $16.3 million in the prior-year quarter. GAAP loss from operations narrowed 10% to $120.3 million.
  4. GAAP net loss was $121.4 million ($(1.15) per ADS), compared with net income of $215.4 million a year earlier, which included a $363 million non-operating BMS arbitration gain and Novartis deferred revenue recognition.
  5. Operating cash flow was $188.4 million, a $267 million improvement year over year, though cash and equivalents declined to $2.71 billion from $3.19 billion at December 31, 2023 over the nine-month period.
  6. SG&A fell to 46% of product sales from 61% a year earlier, showing operating leverage. GAAP gross margin was 83%, reduced by about $17 million of accelerated depreciation tied to tislelizumab production moves.
  7. Pipeline progress included four new molecular entities entering the clinic in Q3 (eight year-to-date), with a goal of 10 or more by year-end 2024, and several Phase 3 starts planned for 2025.

03—Questions

Frequently Asked Questions

  1. Why did collaboration revenue fall so sharply, and does that signal weakness?

    Collaboration revenue fell 96% to $8.2 million from $186.0 million. The prior-year period included about $183 million of remaining deferred revenue from the former Novartis collaborations, recognized after the company reacquired global rights to ociperlimab and TEVIMBRA in 2023. The decline reflects a one-time accounting comparison, not a deterioration in the core business. Product revenue, which rose 67%, is the better indicator of underlying performance.

  2. Is the company now profitable?

    Only on an adjusted, non-GAAP basis in the quarter. Adjusted operating income was $65.6 million, but GAAP loss from operations was $120.3 million and GAAP net loss was $121.4 million. Adjusted results exclude share-based compensation, depreciation and amortization. For the nine months ended September 30, 2024, adjusted operating loss was still $33.2 million, and GAAP operating loss was $488.8 million.

  3. How is BRUKINSA performing, and what drives its growth?

    BRUKINSA is the main growth driver. U.S. sales were $504 million (up 87%) and European sales were $97 million (up 217%). Management attributes the U.S. growth to gains in CLL new patient starts, both frontline and relapsed/refractory, and says BRUKINSA has the broadest label of any BTK inhibitor. Investors should watch continued share gains against competing BTK inhibitors and the upcoming ASH 2024 data for SEQUOIA and BOVen.

  4. Are there near-term concerns about cash, debt, or margins?

    Several items merit monitoring. Cash, cash equivalents and restricted cash fell to $2.71 billion from $3.19 billion at year-end 2023, and debt increased to $1.05 billion from $886 million. Management expects about $17 million of accelerated depreciation tied to the tislelizumab production move in Q4, plus about $2 million in R&D. Continued investment in pipeline and commercial launches could keep GAAP results negative, so the trajectory of operating cash flow will be important.

04—Continue

← View all 8-K filings